🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
NKT
$NKTX
🔒 US EquitiesNkarta Inc
AVG HISTORICAL GAP
+0.44%
MAX GAP RECORD
-22.96%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $NKTX
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$NKTX
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 10, 2026 Earnings Release 2026-11-10 (UNDETERMINED) | 🔮 UPCOMING 🔒 |
| Aug 10, 2026 Earnings Release 2026-08-10 (AFTER CLOSE) |
-4.88%
|
| Mar 25, 2026 Earnings Release 2026-03-25 (AFTER CLOSE) |
+0.00%
|
| Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE) |
+0.00%
|
| Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE) |
+2.04%
|
| May 14, 2025 Earnings Release 2025-05-14 (AFTER CLOSE) |
-4.81%
|
| Mar 26, 2025 Earnings Release 2025-03-26 (AFTER CLOSE) |
+11.68%
|
| Nov 07, 2024 Earnings Release 2024-11-07 (AFTER CLOSE) |
+0.61%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
6.1%
Bullish Gaps (5)
Bearish Gaps (4)
Neutral / Flat (3)
📖 Intelligence Summary
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗